Morgan Stanley ($MS) has issued a less optimistic outlook on the performance of the shares of American pharmaceutical giant ...

Johnson & Johnson JNJ and Pfizer PFE are both healthcare leaders with large drug portfolios and diversified revenue streams, ...

Pfizer (PFE) is reiterated as a Buy, supported by the world's largest drug pipeline and trading below intrinsic value, ...

Pfizer (PFE) shares have shown some movement this week, drawing attention for investors evaluating the company’s current ...

Pfizer Is Still Struggling to Replace Its COVID Revenue. Here's What We Could See From the Pharmaceutical Giant in 2026. Keep ...

Pfizer stock offers 30% upside with strong non-COVID franchises, margin expansion, and pipeline potential. Click here to read ...

Pfizer's stock has been trading at low levels for a while. Diminished growth and concerns about the future have investors thinking twice about the stock. The company did show signs of progress in its ...

The financial metrics highlight JNJ's superiority, with JNJ experiencing a quarterly revenue growth of 6.8% compared to PFE's -5.9%. Furthermore, JNJ's Last 12 Months revenue growth stands at 5.1%, ...

After its best day in nearly four years Tuesday, Pfizer stock gave an encore performance. Shares of the drugmaker closed up 6.8% as investors digested Tuesday's news that Pfizer would get a three-year ...

Delving into the details, we found 35% of traders were bullish, while 65% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $543,015, and 18 were calls, valued ...